Sep 10, 2026 07:30AM
Sep 10, 2026 07:30AM
Sep 8, 2026 07:30AM
Sep 8, 2026 07:30AM
Aug 12, 2026 06:00PM
Jul 27, 2026 08:17AM
Jul 27, 2026 08:17AM Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
Jul 16, 2026 07:30AM
Jul 16, 2026 07:30AM
Jun 22, 2026 07:30AM
Jun 15, 2026 07:30AM
Jun 15, 2026 07:30AM
Jun 8, 2026 07:32AM
Jun 8, 2026 07:30AM Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
Jun 3, 2026 08:00AM
May 28, 2026 08:06AM
May 28, 2026 08:00AM
May 14, 2026 04:30PM
May 6, 2026 07:30AM
May 6, 2026 07:30AM
May 1, 2026 02:30PM GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households Worldwide
Apr 27, 2026 07:39AM
Apr 27, 2026 07:30AM
Apr 27, 2026 07:30AM
Apr 17, 2026 07:31AM
Apr 17, 2026 07:30AM
Apr 15, 2026 07:30AM
Apr 6, 2026 07:31AM Medicus Pharma submits optimized Phase 2 study for Teverelix to FDA
Apr 6, 2026 07:30AM
Apr 1, 2026 07:30AM
Apr 1, 2026 07:30AM
Mar 30, 2026 07:30AM
Mar 30, 2026 07:30AM
Mar 26, 2026 07:30AM
Mar 26, 2026 07:30AM Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
Mar 25, 2026 04:30PM
Mar 18, 2026 07:30AM
Mar 18, 2026 07:30AM
Mar 16, 2026 07:30AM
Mar 16, 2026 07:30AM
Mar 10, 2026 07:30AM
Mar 9, 2026 07:30AM Medicus Pharma reports 73% clearance rate in basal cell carcinoma trial
Mar 9, 2026 07:30AM
Mar 5, 2026 07:30AM
Mar 5, 2026 07:30AM
Mar 3, 2026 07:30AM
Feb 12, 2026 07:30AM
Feb 10, 2026 07:31AM
Feb 10, 2026 07:30AM Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
Jan 23, 2026 07:30AM

330,719 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All